Although it has been well recognized that EGFR mutation is strongly associated with the therapeutic effect of TKIs in NSCLC patients, most patients could not provide the tumor tissues that needed for the mutation test [5,12]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.